Edwards Lifesciences Corporation (EW) Stock Analysis & Winston Score

Edwards Lifesciences makes medical devices that help the heart work properly. Its most important product is a small valve that doctors insert into a patient's heart without open-chest surgery — a procedure called TAVR (transcatheter aortic valve replacement). Hospitals and cardiac surgeons around the world use Edwards products to treat patients with diseased or failing heart valves. The company earns money by selling these devices directly to hospitals, which then use them during procedures. Edwards operates globally, with the United States being its largest market, and it generates roughly $6 billion in annual revenue. Its strong competitive position comes from years of clinical data, deep relationships with surgeons, and patents protecting its valve technology. The key growth driver is an aging global population that will need more heart valve procedures over time, though the main risk is increasing competition from rivals like Medtronic and Boston Scientific, which are developing their own transcatheter valve products.